ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced that it intends to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty (30) day option to purchase up to 750,000 additional shares to cover over-allotments, if any.
Tags: ImmunoGen, SharesCurrently viewing and reading
Related Post
- Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings (September 22nd, 2009)
- Walter Energy Announces Second Quarter 2009 Earnings of $0.21 Per Diluted Share (July 24th, 2009)
- Discover Financial Services Announces Pricing of Public Offering of Common Stock (July 8th, 2009)
- Acxiom Announces First-Quarter Expectations (June 26th, 2009)
- Harman International Industries Prices Common Stock Offering at $18.75 Per Share for Gross Proceeds of $200 Million (June 21st, 2009)
Business News
- Intel Fourth-Quarter Net Income $2.3 Billion, Up 875%
- Kodak Announces Institutional Investor Meeting
- LED Backlit LCD Monitor Panels Expected to Reach 22% Share in Q3’10
- Philips updates markets on Healthcare sector in meeting with financial analysts
- HK McDonald’s head convicted in bribery case
- Autodesk Settles German Copyright Infringement Case
- AMD Extends the Mainstream Value of Dragon Platform Technology with 45nm AMD Phenom II Triple-Core Processors
- Elbit Systems’ Subsidiary, Elisra, Awarded a Contract Valued at $60 Million
- AT&T to Acquire Centennial Communications
- Dailymotion Brings Video to One Laptop per Child Foundation’s XO Laptop
No Comment Received
Leave A Reply